Prognostic biomarkers are those that indicate an increased (or decreased) likelihood of a future clinical event, disease relapse or progression in a defined population. Ace Therapeutics utilizes our expertise and advanced technologies to help clients identify and validate biomarkers associated with the prognosis of specific psychiatric disorders. These biomarkers can be used to predict disease trends, treatment response, and long-term health outcomes.

Introduction of Prognostic Biomarkers

Prognostic biomarkers can indicate the likelihood of an increase or decrease in future clinical events, as well as disease recurrence or progression in a given population. The presence and intensity of prognostic biomarkers may vary depending on the setting of the clinical trial protocol, e.g., treatment differences, disease stage, etc., and especially the choice of clinical endpoints. In clinical trials, prognostic biomarkers are used to identify patients who are more likely to experience a clinical event or disease progression, thus identifying populations at higher risk. Another use of prognostic biomarkers is for treatment selection. They can provide information about the safety of a treatment.

Our Prognostic Biomarker Development Services

Our prognostic biomarker development service for psychiatric disorders, relying on cutting-edge molecular biology technology and big data analysis, is dedicated to accurately identifying prognostic biomarkers related to psychiatric disorders from individual biological samples. Our key service processes include the following:

• Biomarker identification and validation

We use high-throughput screening techniques combined with bioinformatics analysis to identify potential prognostic biomarkers from multi-omics data including genomics, proteomics and metabolomics.

• Sample analysis

We perform in-depth laboratory analysis of blood, cerebrospinal fluid and other clinical samples provided by our clients to verify the clinical relevance and predictive value of biomarkers.

• Statistical analysis and modeling

We used advanced bioinformatics tools to build predictive models to assess the predictive accuracy of biomarkers in different groups of psychiatric disorders.

Advantages of Our Prognostic Biomarker Development Services

• We are committed to helping our clients identify prognostic biomarkers for psychiatric disorders using ex vivo and in vivo preclinical modeling and robust analytical methods.
• Our services encompass a comprehensive assessment of genes, proteins, metabolites and neuroimaging at multiple levels to ensure that we provide our clients with accurate prognostic biomarkers for psychiatric disorders.
• A professional analytical team and rigorous quality control process ensure the accuracy and reliability of each report.

Ace Therapeutics is committed to helping you accelerate the identification of prognostic biomarkers for psychiatric disorders using our platform technology. Please contact us for more details and we will be happy to assist you.